A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy
Advanced Science · 2025
DOI: 10.1002/advs.202411378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yiming Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, and Interna…. Hauptthemen laut MEDLINE: Nanomedicine, Glucose, B7-H1 Antigen, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China Key Program, Natural Science Foundation of China, Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Combination therapy has become a promising strategy for promoting the outcomes of anti‐programmed death ligand‐1 (αPD‐L1) therapy in lung cancer. Among all, emerging strategies targeting cancer metabolism have shown great potency in treating cancers with immunotherapy. Here, alteration in glucose and copper metabolisms is found to synergistically regulate PD‐L1 expression in lung cancer cells. Thus, an intelligent biomimetic nano‐delivery system is synthesized by camouflaging lung cancer cell membranes onto glucose oxidase‐loaded Cu‐LDHs (CMGCL) for cancer metabolism targeted interference. Such novel nanomedicine is able to induce lung cancer cell cuproptosis and PD‐L1 upregulation significantly via self‐amplified cascade reactions. Meanwhile, with a decent cancer cell membrane coating, CMGCL exhibited great biosafety, tumor‐targeted efficiency and anti‐tumor effects in LLC lung tumor‐bearing mice models. Additionally, a combination of CMGCL can sensitize the therapeutic effects of αPD‐L1, substantially promoting tumor inhibition in both subcutaneous and lung metastasis LLC‐bearing mice models. Overall, these findings highlight the potential connections between glucose metabolism and cell cuproptosis, offering a promising approach for treating lung cancer by integrating starvation, cuproptosis, and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zheji…
- Zhejiang Key Laboratory of Precision Diagnosis and Treatment for Lung Cancer, Yiwu, 322000, China.
- College of Jiyang, Zhejiang A&F University, Zhuji, 311800, China.
- Department of Nuclear Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150000, China.
ORCID-Profile: Yiming Xu, Weiyu Chen, Kai Wang
Förderung
- Natural Science Foundation of China Key Program
- Natural Science Foundation of China
- Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China
- Major project of Science and Technology Program of Jinhua
- National Natural Science Foundation of China
Zitieren
APA
Xu, Y., Wu, Y., Zheng, X., Wang, D., Ni, H., Chen, W., & Wang, K. (2025). A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy. Advanced Science. https://doi.org/10.1002/advs.202411378
Vancouver
Xu Y, Wu Y, Zheng X, Wang D, Ni H, Chen W, et al. A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy. Advanced Science. 2025. doi:10.1002/advs.202411378
BibTeX
@article{Xu2025,
author = {Xu, Yiming and Wu, Yuan and Zheng, Xinjie and Wang, Dongxue and Ni, Hangqi and Chen, Weiyu and Wang, Kai},
title = {A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411378}
}
EUVIMED